KEYNOTE-180 also showed a great response in ESCC (Shah et al., 2019b), and ultimately, PD-L1 therapy was approved by the Food and Drug Administration to treat ESCC. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.